Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVieBIVI -3.05%34 9-Day RSI is 35.96 as of Jul. 14, 2026. GuruFocus rates BIVI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, BioVie ranks better than 78.9% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-14), BioVie's 9-Day RSI is 35.96.
The industry rank for BioVie's 9-Day RSI or its related term are showing as below:
BIVI's 9-Day RSI is ranked better than 78.9% of 1422
companies
in the Biotechnology industry
Industry Median: 47.095
vs BIVI: 35.96
BioVie (NAS:BIVI) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
BioVie 9-Day RSI Related Terms
BIVI vs CYCN, LNAI, CTXR: 9-Day RSI Comparison
For the Biotechnology subindustry, BioVie's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVie 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVie's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where BioVie's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVie (BIVI) has a 9-Day RSI of 35.96 as of Jul. 14, 2026. According to the industry distribution chart, BioVie ranks #300 out of 1422 companies in the Biotechnology industry, placing it in the top 21.1%.
Is BioVie's 9-Day RSI too high?
BioVie's current 9-Day RSI is 35.96. The Biotechnology industry median 9-Day RSI is 47.10. BioVie's value of 35.96 is 23.6% below this industry median. Based on the distribution chart, BioVie ranks #300 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioVie has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BioVie's 9-Day RSI compare to CYCN and LNAI?
According to the Biotechnology industry distribution chart, BioVie ranks #300 out of 1422 companies for 9-Day RSI. This places BioVie in the top 21% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 47.10. BioVie's value of 35.96 is 23.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 47.10, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioVie's current 9-Day RSI of 35.96 is 23.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 47.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVie's current 9-Day RSI is 35.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVie stock overvalued right now?
BioVie (BIVI) has a current 9-Day RSI of 35.96. The current 9-Day RSI is 35.96 and 23.6% below the Biotechnology industry median of 47.10. BioVie's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For BioVie (BIVI), the current 9-Day RSI is 35.96 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
34GF Score
Get the complete analysis for BIVI
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIVI has been successfully added to your 
